"Doxapram"@en . . . . . . . . . . . . "A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)"@en . . . . . . . . . . . . . . . . "Humans and other mammals"@en . . . "# Singh P, Dimitriou V, Mahajan RP, Crossley AW: Double-blind comparison between doxapram and pethidine in the treatment of postanaesthetic shivering. Br J Anaesth. 1993 Nov;71(5):685-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8251281 # Yost CS: A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17227289"@en . . . . "approved"@en . . . . "For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease."@en . . . . . "309-29-5"@en . "Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels."@en . . . . "Doxapramum"@en . . . . . . . . . "1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone"@en . . "Doxapram"@en . "Lunsford, C.D. and Cale, A.D. Jr.; U S . Patent 3,192,230; June 29, 1965; assigned to A.H. Robins Company, Inc."@en . . "Intravenous LD₅₀ values in the mouse and rat were approximately 75 mg/kg and in the cat and dog were 40 to 80 mg/kg. Symptoms of overdosage are extensions of the pharmacologic effects of the drug. Excessive pressor effect, tachycardia, skeletal muscle hyperactivity, and enhanced deep tendon reflexes may be early signs of overdosage."@en . "(+-)-Doxapram"@en . " "@en . . .